SB Drug Discovery
SB Drug Discovery is a part of Sygnature Discovery, specializing in cellular pharmacology services with a focus on ion channels, GPCRs, transporters, and neurodegenerative disease research. They offer custom cell line generation, high-throughput screening, electrophysiology, and assay development to support drug discovery. The company has a global reputation for outstanding customer service and innovative research, with a history of delivering novel drug candidates and supporting early-stage drug discovery.
Industries
Nr. of Employees
small (1-50)
SB Drug Discovery
Glasgow, Glasgow City, United Kingdom, Europe
Products
Custom assay-ready cell lines
Validated, stable recombinant cell lines tailored for ion channel, GPCR and transporter assays and compatible with electrophysiology and diverse functional readouts.
High-throughput iPSC-derived DRG electrophysiology platform
A scalable automated electrophysiology platform employing iPSC-derived dorsal root ganglion neurons for physiologically relevant ion channel screening, concentration-response profiling and compound testing.
SSM-based transporter electrophysiology platform (96-well)
A 96-well, solid-supported membrane automated electrophysiology platform for label-free, high-throughput transporter function assessment and lead optimisation.
Custom assay-ready cell lines
Validated, stable recombinant cell lines tailored for ion channel, GPCR and transporter assays and compatible with electrophysiology and diverse functional readouts.
High-throughput iPSC-derived DRG electrophysiology platform
A scalable automated electrophysiology platform employing iPSC-derived dorsal root ganglion neurons for physiologically relevant ion channel screening, concentration-response profiling and compound testing.
SSM-based transporter electrophysiology platform (96-well)
A 96-well, solid-supported membrane automated electrophysiology platform for label-free, high-throughput transporter function assessment and lead optimisation.
Services
Custom design and delivery of stable, validated recombinant and assay-ready cell lines to support ion channel, GPCR and transporter assays and complex multi-gene constructs.
Tailored ion channel solutions including high-throughput screening, automated electrophysiology, subtype panels and pharmacological profiling to support hit identification and lead optimisation.
GPCR assay development, chimeric G-protein coupling optimisation, and functional readouts (cAMP, calcium, IP1) for high-throughput screening and lead profiling.
Transporter-expressing cell line design and high-throughput, label-free transporter functional screening using SSM-based automated electrophysiology for electrogenic transporter characterisation.
End-to-end screening support including primary HTS, follow-up profiling, selectivity testing and data generation using a mix of fluorescence assays and automated electrophysiology.
Assay portfolio and screening cascades for mitochondrial endpoints (OCR, ATP/ADP, NAD/NADH, membrane potential, calcium and oxidative stress) available in medium- and high-throughput formats.
Custom design and delivery of stable, validated recombinant and assay-ready cell lines to support ion channel, GPCR and transporter assays and complex multi-gene constructs.
Tailored ion channel solutions including high-throughput screening, automated electrophysiology, subtype panels and pharmacological profiling to support hit identification and lead optimisation.
GPCR assay development, chimeric G-protein coupling optimisation, and functional readouts (cAMP, calcium, IP1) for high-throughput screening and lead profiling.
Transporter-expressing cell line design and high-throughput, label-free transporter functional screening using SSM-based automated electrophysiology for electrogenic transporter characterisation.
End-to-end screening support including primary HTS, follow-up profiling, selectivity testing and data generation using a mix of fluorescence assays and automated electrophysiology.
Assay portfolio and screening cascades for mitochondrial endpoints (OCR, ATP/ADP, NAD/NADH, membrane potential, calcium and oxidative stress) available in medium- and high-throughput formats.
Expertise Areas
- Ion channel and receptor pharmacology
- Custom cell line generation
- Automated electrophysiology and high-throughput electrophysiology
- Transporter functional screening
Key Technologies
- Automated patch-clamp
- Solid-supported membrane (SSM) electrophysiology (96-well)
- High-throughput fluorescence-based screening (HTS)
- Radioligand binding assays
News & Updates
Engage with us at our exhibition booth at the Pennsylvania Convention Centre, February 10th-14th, to experience our ion channel and receptor drug discovery capabilities.
Join us in Washington, D.C., November 12th-15th for the inaugural joint appearance of SB Drug Discovery, Sygnature Discovery, and NuChem Sciences at SfN's annual Neuroscience conference.
Announcement of integration of SURFE2R 96SE platform for high throughput electrophysiology, supporting transporter research and lead optimization.
Sygnature Discovery's acquisition of NuChem Sciences, a major North American discovery CRO, expanding its global footprint and capabilities.
Sygnature Discovery completes acquisition of SB Drug Discovery to strengthen its market-leading capabilities.
Engage with us at our exhibition booth at the Pennsylvania Convention Centre, February 10th-14th, to experience our ion channel and receptor drug discovery capabilities.
Join us in Washington, D.C., November 12th-15th for the inaugural joint appearance of SB Drug Discovery, Sygnature Discovery, and NuChem Sciences at SfN's annual Neuroscience conference.
Announcement of integration of SURFE2R 96SE platform for high throughput electrophysiology, supporting transporter research and lead optimization.
Sygnature Discovery's acquisition of NuChem Sciences, a major North American discovery CRO, expanding its global footprint and capabilities.
Sygnature Discovery completes acquisition of SB Drug Discovery to strengthen its market-leading capabilities.